ClinicalTrials.gg
TerminatedNCT04421456Updated Jun 15, 2023Results posted

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

A Phase 2 interventional study of GWP42003-P and Placebo in Schizophrenia, sponsored by Jazz Pharmaceuticals. Terminated at 39 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was terminated based on a business decision by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing cannabidiol in Schizophrenia — none open to participants now, none under way, none of them phase 3. Cannabidiol · Schizophrenia.

Enrollment
2nd of 10
95 · median 42
Started
2020
the only one that year
Phase 2
7 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Jazz Pharmaceuticals

Among the 10 studies testing cannabidiol in Schizophrenia, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 2, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 10 studies testing cannabidiol in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing cannabidiol in Schizophrenia as a file.
02

Study summary

This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • GWP42003-P
  • adjunctive therapy
  • inadequate response to ongoing antipsychotic treatment
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 to 55 years of age at the time of signing the Form (ICF)
  • Willing and able to give informed consent for participation in the trial
  • (DSM-5) diagnosis of schizophrenia, confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Clinically stable outpatient
  • Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) score of ≥ 60 and \< 110 at screening and baseline visits
  • Score of ≥ 4 for at least 2 of the following PANSS items: delusions (P1), conceptual disorganization (P2), hallucinatory behavior (P3), suspiciousness (P6), somatic concern (G1), or unusual thought content (G9) at screening visit
  • Score ≥ 4 (at least moderately ill) on the Clinical Global Impression of Severity (CGI-S) at screening visit.
  • Undergoing treatment with at least 1 antipsychotic medication with no change in dosing, supported by documentation, for at least 8 weeks prior to screening and no change in antipsychotic medication dosing planned throughout the trial
  • Taking a maximum of 2 antipsychotic medications. For participants taking oral antipsychotic medications only, the sum of primary and secondary antipsychotic medications is ≤ 30 milligrams (mg)/day of oral olanzapine equivalents. For participants taking long-acting injectable antipsychotic medications, the dose is within the range approved and any secondary oral antipsychotic medications is ≤ 5 mg/day of oral olanzapine equivalents.
  • Documented response (at least partially) to treatment with current antipsychotic medications (e.g., treatment of recent exacerbation of psychotic symptoms)
  • On a stable dose if taking concomitant psychotropic medications and within allowed limits, including antidepressants, anxiolytics, anticholinergics and/or antiepileptics for at least 4 weeks prior to screening (dose reductions ≤ 25% of total dose are permitted) with no plans to change dosing during the trial (i.e., from screening onwards). Valproic acid or any prescribed valproate product (valproate semisodium or valproate sodium) is disallowed within 4 weeks (i.e., more than 5 half lives) prior to the baseline visit.

Exclusion criteria

Exclusion Criteria:

Diagnosis and Psychiatric History

  • Recent (within the last 3 months prior to screening) diagnosis of panic disorder, depressive episode, or other comorbid psychiatric conditions based on the MINI for Psychotic Disorders Studies (or ) OR has PANSS item G6 score of ≥ 5 (depression) at screening.
  • Any psychiatric disorder that may interfere with the conduct of this trial, including but not limited to attention deficit hyperactivity disorder, pervasive developmental disorder, intellectual disability, personality disorder that might interfere with compliance or increase suicidal risk, manic or hypomanic episode, or any other psychotic disorder, as defined in the DSM-5
  • Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 6 months prior to screening or prior chronic substance abuse judged likely to recur during the trial period by the investigator. Nicotine use or occasional cannabis use (≤ 3 days per week recreational cannabis use) is acceptable. Corroboration of the participant's frequency of cannabis use by an adult informant (e.g., family member, social worker, caseworker, residential facility staff, or nurse), should be obtained if the participant has a positive urine test for Δ9-tetrahydrocannabinol at screening.
  • A positive drug screen for opiates, methadone, cocaine, amphetamines (including ecstasy), or barbiturates; a repeat drug screen may be done to verify the result.
  • Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the adult C-SSRS or within 1 month prior to screening

Treatment History

  • Treatment-resistant schizophrenia as judged by the treating physician and as defined by having previously demonstrated no response to > 2 trials of antipsychotic trial medications at therapeutic doses or required clozapine therapy due to non-response to antipsychotic therapy within the previous 6 months.
  • Based on the investigator assessment, current antipsychotic medication blood levels are below the therapeutic range if therapeutic drug monitoring is available for the antipsychotic(s) prescribed for the participant; or there is no documentation confirming the administration of long-acting injectable antipsychotic medication within the approved dose range and as prescribed by the treating physician.

Past and Current Medical History

  • History of moderate or severe head trauma (for example, loss of consciousness for more than 15 minutes) or other neurological disorders (including epilepsy), neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, etc.) or systemic medical diseases that are, in the opinion of the investigator, likely to interfere with the conduct of the trial or confound the trial assessments
  • Tardive dyskinesia (TD) that is moderate to severe (i.e., a score of > 21 on the dyskinesia subscale of the Extrapyramidal Symptom Rating Scale [ESRS] at screening) or requires treatment
  • Any other significant disease, disorder, pending court proceedings or social circumstances which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.

Other

  • Any known or suspected to cannabinoids or any of the of the medicinal product, such as sesame seed oil
  • One or more laboratory values outside the normal range, based on the blood or urine samples taken at the screening visit, that are considered by the investigator to be ; or impaired hepatic function at screening, defined as serum (ALT) or aspartate aminotransferase (AST) > 2 × (ULN) or total (TBL) > 1.5 × ULN or (INR) > 1.2 (TBL ULN parameter not applicable for participants diagnosed with Gilbert's disease)
  • Currently using or within 3 months of screening has used cannabidiol (CBD) oil or purified CBD preparations and is unwilling to abstain for the duration of the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    GWP42003-P 300 mg

    GWP42003-P 300 milligrams (mg) per day

    Drug: GWP42003-P

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

  • Experimental
    GWP42003-P 1000 mg

    GWP42003-P 1000 mg per day

    Drug: GWP42003-P

Interventions

  • oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring

  • DrugPlacebo

    oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring

06

What researchers measure

Primary outcomes

  1. Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score

    The PANSS-T is a medical scale used for measuring symptom severity of participants with schizophrenia or related psychotic disorder. It is a 30-item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. A PANSS-T score is derived from the sum of the 30 items and the total score ranges from 30 to 210, where higher scores represent worse outcome. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

    Time frame: Baseline up to Week 12

  2. Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score

    The PANSS 'P' Scale was calculated as the sum of the items prefixed with an P, 7 items in total, i.e. delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

    Time frame: Baseline up to Week 12

  3. Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score

    The PANSS 'N' Scale will be calculated as the sum of the items prefixed with an N, 7 items in total, i.e. blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

    Time frame: Baseline up to Week 12

  4. Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score

    The PANSS 'G' Scale will be calculated as the sum of the items prefixed with a G, 16 items in total, i.e. somatic concerns, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

    Time frame: Baseline up to Week 12

  5. Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score

    The CGI-S is a 7-point scale used to rate the severity of participants' illness at the time of assessment. Considering total clinical experience, a participant will be assessed on severity of mental illness at the time of rating 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = among the most extremely ill participants. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

    Time frame: Baseline up to Week 12

  6. Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12

    The CGI-I is a 7-point scale used to rate the improvement of participants' condition at the time of assessment. Compared to the patient's condition at baseline, the participants' condition was rated as 1 = very much improved since initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. Higher scores indicate a worse outcome. The number of participants with minimally or better improvements (score of 3 or better) are being reported.

    Time frame: Week 12

Secondary outcomes

  1. Mean Change From Baseline in Body Weight

    Time frame: Baseline up to Week 12

  2. Mean Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline up to Week 12

  3. Mean Change From Baseline in Waist Circumference

    Time frame: Baseline up to Week 12

  4. Mean Change From Baseline in Blood Pressure

    Time frame: Baseline up to Week 12

  5. Mean Change From Baseline in Heart Rate

    Time frame: Baseline up to Week 12

  6. Mean Change From Baseline in Respiratory Rate

    Time frame: Baseline up to Week 12

  7. Mean Change From Baseline in Temperature

    Time frame: Baseline up to Week 12

  8. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results

    Time frame: Day 85

  9. Number of Participants With Defined Flagged Electrocardiogram (ECG) Parameter Values

    Time frame: Day 85

  10. Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a short questionnaire that is used to assess suicidal ideation (5 questions) and behavior (5 questions) since last patient visit. The questionnaire is completed by participants answering yes or no to each question.

    Time frame: Baseline (screening) up to Day 85

07

Results

Posted Jun 15, 2023

Participant flow

A total of 95 participants who met all inclusion and no exclusion criteria were enrolled in the study and were randomized to the Placebo Run-in Period. Eighteen participants failed the Placebo Run-in Period. A total of 77 participants were randomized to 1 of 2 GWP42003-P doses or placebo treatment at a 2:2:1:1 ratio at 33 clinic centers.

Randomized Placebo Run-in Period
Participant flow — Randomized Placebo Run-in Period
MilestoneGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Started0095
Completed0077
Not completed0018
Withdrew: Placebo run-in failures0018
Randomized Treatment Period
Participant flow — Randomized Treatment Period
MilestoneGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Started272426
Completed231919
Not completed457
Withdrew: Adverse event010
Withdrew: Withdrawal of parent/legal representative consent101
Withdrew: Lost to follow-up221
Withdrew: Participant non-compliance112
Withdrew: Other013

Outcome measures

PrimaryLeast Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score

The PANSS-T is a medical scale used for measuring symptom severity of participants with schizophrenia or related psychotic disorder. It is a 30-item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. A PANSS-T score is derived from the sum of the 30 items and the total score ranges from 30 to 210, where higher scores represent worse outcome. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · units on a scale
Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score
units on a scaleGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score-10.49 ± 1.64-10.69 ± 1.75-8.74 ± 1.78
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.4528 · Least square mean difference: -1.75 · 95% CI -6.35 to 2.84
  • GWP42003-P 1000 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.4226 · Least square mean difference: -1.96 · 95% CI -6.76 to 2.85
PrimaryLeast Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score

The PANSS 'P' Scale was calculated as the sum of the items prefixed with an P, 7 items in total, i.e. delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · units on a scale
Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score
units on a scaleGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score-3.16 ± 0.59-3.75 ± 0.63-2.53 ± 0.62
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.4479 · Least square mean difference: -0.63 · 95% CI -2.25 to 1.00
  • GWP42003-P 1000 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.1616 · Least square mean difference: -1.22 · 95% CI -2.92 to 0.49
PrimaryLeast Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score

The PANSS 'N' Scale will be calculated as the sum of the items prefixed with an N, 7 items in total, i.e. blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · units on a scale
Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score
units on a scaleGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score-2.64 ± 0.53-1.57 ± 0.56-2.33 ± 0.58
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.6787 · Least square mean difference: -0.31 · 95% CI -1.80 to 1.18
  • GWP42003-P 1000 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.3351 · Least square mean difference: 0.76 · 95% CI -0.79 to 2.30
PrimaryLeast Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score

The PANSS 'G' Scale will be calculated as the sum of the items prefixed with a G, 16 items in total, i.e. somatic concerns, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · units on a scale
Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score
units on a scaleGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score-4.78 ± 1.03-4.91 ± 1.10-3.68 ± 1.09
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.4504 · Least square mean difference: -1.10 · 95% CI -3.96 to 1.76
  • GWP42003-P 1000 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.4195 · Least square mean difference: -1.23 · 95% CI -4.22 to 1.76
PrimaryLeast Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score

The CGI-S is a 7-point scale used to rate the severity of participants' illness at the time of assessment. Considering total clinical experience, a participant will be assessed on severity of mental illness at the time of rating 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = among the most extremely ill participants. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · units on a scale
Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score
units on a scaleGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score-0.47 ± 0.11-0.50 ± 0.12-0.45 ± 0.12
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.8850 · Least square mean difference: 0.02 · 95% CI -0.35 to 0.30
  • GWP42003-P 1000 mg vs Pooled Placebo · Mixed-effects repeated measures model · p = 0.7808 · Least square mean difference: 0.04 · 95% CI -0.36 to 0.27
PrimaryNumber of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12

The CGI-I is a 7-point scale used to rate the improvement of participants' condition at the time of assessment. Compared to the patient's condition at baseline, the participants' condition was rated as 1 = very much improved since initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. Higher scores indicate a worse outcome. The number of participants with minimally or better improvements (score of 3 or better) are being reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12
ParticipantsGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12171215
Statistical analysis
  • GWP42003-P 300 mg vs Pooled Placebo · Regression, Logistic · p = 0.6707 · Odds ratio (or): 1.412 · 95% CI 0.288 to 6.924
  • GWP42003-P 1000 mg vs Pooled Placebo · Regression, Logistic · p = 0.4883 · Odds ratio (or): 0.576 · 95% CI 0.121 to 2.744
SecondaryMean Change From Baseline in Body Weight
Time frame:
Baseline up to Week 12
Reported as:
Mean · kilogram
Mean Change From Baseline in Body Weight
kilogramGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Body Weight-0.03 ± 3.09-0.14 ± 1.981.37 ± 1.28
SecondaryMean Change From Baseline in Body Mass Index (BMI)
Time frame:
Baseline up to Week 12
Reported as:
Mean · kg/m^2
Mean Change From Baseline in Body Mass Index (BMI)
kg/m^2GWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Body Mass Index (BMI)0 ± 0.98-0.04 ± 0.660.45 ± 0.45
SecondaryMean Change From Baseline in Waist Circumference
Time frame:
Baseline up to Week 12
Reported as:
Mean · centimeters
Mean Change From Baseline in Waist Circumference
centimetersGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Waist Circumference0.41 ± 5.36-0.53 ± 2.071.34 ± 3.13
SecondaryMean Change From Baseline in Blood Pressure
Time frame:
Baseline up to Week 12
Reported as:
Mean · mmHg
Mean Change From Baseline in Blood Pressure
mmHgGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Diastolic blood pressure1.7 ± 6.190 ± 7.05-0.2 ± 5.71
Systolic blood pressure0.3 ± 9.380 ± 8.410.3 ± 5.66
SecondaryMean Change From Baseline in Heart Rate
Time frame:
Baseline up to Week 12
Reported as:
Mean · beats/minute
Mean Change From Baseline in Heart Rate
beats/minuteGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Heart Rate1.0 ± 8.46-3.1 ± 9.130.1 ± 6.52
SecondaryMean Change From Baseline in Respiratory Rate
Time frame:
Baseline up to Week 12
Reported as:
Mean · breaths/minute
Mean Change From Baseline in Respiratory Rate
breaths/minuteGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Respiratory Rate-0.6 ± 2.130.1 ± 1.370 ± 1.45
SecondaryMean Change From Baseline in Temperature
Time frame:
Baseline up to Week 12
Reported as:
Mean · Celsius
Mean Change From Baseline in Temperature
CelsiusGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Mean Change From Baseline in Temperature-0.07 ± 0.340.06 ± 0.20-0.02 ± 0.19
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results
Time frame:
Day 85
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results
ParticipantsGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Supine systolic blood pressure, Day 85: <-20000
Supine systolic blood pressure, Day 85: >20100
Supine diastolic blood pressure, Day 85: <-10010
Supine diastolic blood pressure, Day 85: >10210
Heart rate, Day 85: <-20000
Heart rate, Day 85: >20000
Weight, Day 85: ≤-7%210
Weight, Day 85: ≥7%100
SecondaryNumber of Participants With Defined Flagged Electrocardiogram (ECG) Parameter Values
Time frame:
Day 85
Reported as:
Count of participants · Participants
Number of Participants With Defined Flagged Electrocardiogram (ECG) Parameter Values
ParticipantsGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
QTcF interval, Day 85: >450 msec010
QTcF interval, Day 85: >480 msec000
QTcF interval, Day 85: >500 msec000
SecondaryNumber of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a short questionnaire that is used to assess suicidal ideation (5 questions) and behavior (5 questions) since last patient visit. The questionnaire is completed by participants answering yes or no to each question.

Time frame:
Baseline (screening) up to Day 85
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo
Screening, Suicidal ideation, Wish to be dead100
Screening, Suicidal ideation, Non-specific active suicidal thoughts000
Screening, Suicidal ideation, Active with any methods (not planned) without intent to act000
Screening, Suicidal ideation, Active with some intent to act, without specific plan000
Screening, Suicidal ideation, Active with specific plan and intent000
Screening, Suicidal behavior, Preparatory acts or behavior000
Screening, Suicidal behavior, Aborted attempt000
Screening, Suicidal behavior, Interrupted attempt000
Screening, Suicidal behavior, Actual attempt000
Screening, Suicidal behavior, Completed suicide000
Day 14, Suicidal ideation, Wish to be dead010
Day 14, Suicidal ideation, Non-specific active suicidal thoughts000
Day 14, Suicidal ideation, Active with any methods (not planned) without intent to act000
Day 14, Suicidal ideation, Active with some intent to act, without specific plan000
Day 14, Suicidal ideation, Active with specific plan and intent000
Day 14, Suicidal behavior, Preparatory acts or behavior000
Day 14, Suicidal behavior, Aborted attempt000
Day 14, Suicidal behavior, Interrupted attempt000
Day 14, Suicidal behavior, Actual attempt000
Day 14, Suicidal behavior, Completed suicide000
Day 29, Suicidal ideation, Wish to be dead110
Day 29, Suicidal ideation, Non-specific active suicidal thoughts010
Day 29, Suicidal ideation, Active with any methods (not planned) without intent to act010
Day 29, Suicidal ideation, Active with some intent to act, without specific plan000
Day 29, Suicidal ideation, Active with specific plan and intent000
Day 29, Suicidal behavior, Preparatory acts or behavior000
Day 29, Suicidal behavior, Aborted attempt000
Day 29, Suicidal behavior, Interrupted attempt000
Day 29, Suicidal behavior, Actual attempt000
Day 29, Suicidal behavior, Completed suicide000
Day 85, Suicidal ideation, Wish to be dead000
Day 85, Suicidal ideation, Non-specific active suicidal thoughts000
Day 85, Suicidal ideation, Active with any methods (not planned) without intent to act000
Day 85, Suicidal ideation, Active with some intent to act, without specific plan000
Day 85, Suicidal ideation, Active with specific plan and intent000
Day 85, Suicidal behavior, Preparatory acts or behavior000
Day 85, Suicidal behavior, Aborted attempt000
Day 85, Suicidal behavior, Interrupted attempt000
Day 85, Suicidal behavior, Actual attempt000
Day 85, Suicidal behavior, Completed suicide000

Adverse events

Collected over All adverse events (AEs) were collected from baseline up to end of study, approximately 1 year 8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 300 mg0/27 (0%)2/27 (7.4%)3/27 (11.1%)
GWP42003-P 1000 mg0/24 (0%)2/24 (8.3%)3/24 (12.5%)
Pooled Placebo (Treatment Period)0/26 (0%)1/26 (3.8%)3/26 (11.5%)
Pooled Placebo (Placebo Run-In Period)0/95 (0%)0/95 (0%)0/95 (0%)
Most frequent serious events
Most frequent serious events
EventGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo (Treatment Period)Pooled Placebo (Placebo Run-In Period)
COVID-19Infections and infestations2/270/240/26—
Coronavirus infectionInfections and infestations0/271/240/26—
UrticariaSkin and subcutaneous tissue disorders0/271/240/26—
HospitalizationSurgical and medical procedures0/270/241/26—
Most frequent other events
Most frequent other events
EventGWP42003-P 300 mgGWP42003-P 1000 mgPooled Placebo (Treatment Period)Pooled Placebo (Placebo Run-In Period)
HeadacheNervous system disorders1/273/243/260/95
COVID-19Infections and infestations2/270/240/260/95

Baseline characteristics

Demographics and baseline characteristics were assessed in the Full Analysis Set in the Treatment Period.

Age, Categorical
Age, Categorical(Participants)GWP42003-P 300 mgGWP42003-P 1000 mgPooled PlaceboTotal
<=18 years0000
Between 18 and 65 years27242677
>=65 years0000
Age, Continuous
Age, Continuous(years)GWP42003-P 300 mgGWP42003-P 1000 mgPooled PlaceboTotal
Mean37.5 ± 7.5339.2 ± 8.2138.7 ± 8.8738.4 ± 8.13
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 300 mgGWP42003-P 1000 mgPooled PlaceboTotal
Female67720
Male21171957
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GWP42003-P 300 mgGWP42003-P 1000 mgPooled PlaceboTotal
American Indian or Alaska Native0000
Asian0022
Native Hawaiian or Other Pacific Islander1001
Black or African American1171028
White15171446
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)GWP42003-P 300 mgGWP42003-P 1000 mgPooled PlaceboTotal
United States20141852
Poland1113
Serbia68620
Spain0112
08

Study locations

39 sites
  • Clinical Trial Site
    Bentonville, Arkansas 72712, United States
  • Clinical Trial Site
    Little Rock, Arkansas 72211-3702, United States
  • Clinical Trial Site
    Garden Grove, California 92845, United States
  • Clinical Trial Site
    Lemon Grove, California 91945, United States
  • Clinical Trial Site
    Oakland, California 94607-3900, United States
  • Clinical Trial Site
    Pico Rivera, California 90660-4920, United States
  • Clinical Trial Site
    Largo, Florida 33770, United States
  • Clinical Trial Site
    Lauderhill, Florida 33319, United States
  • Clinical Trial Site
    Tampa, Florida 33614, United States
  • Clinical Trial Site
    Lincolnwood, Illinois 60712, United States
  • Clinical Trial Site
    Shreveport, Louisiana 71101, United States
  • Clinical Trial Site
    Saint Louis, Missouri 63118, United States
  • Clinical Trial Site
    Las Vegas, Nevada 89102, United States
  • Clinical Trial Site
    Berlin, New Jersey 08009, United States
  • Clinical Trial Site
    Cedarhurst, New York 11516, United States
  • Clinical Trial Site
    New York, New York 10035, United States
  • Clinical Trial Site
    Rochester, New York 14618, United States
  • Clinical Trial Site
    Beachwood, Ohio 44122, United States
  • Clinical Trial Site
    Richardson, Texas 75080, United States
  • Clinical Trial Site
    Belchatow, 97-400, Poland
  • Clinical Trial Site
    Gdansk, 80-438, Poland
  • Clinical Trial Site
    Kielce, 25-411, Poland
  • Clinical Trial Site
    Kobierzyce, 55-040, Poland
  • Clinical Trial Site
    Poznan, 60-369, Poland
  • Clinical Trial Site
    Torun, 87-100, Poland
  • Clinical Trial Site
    Wroclaw, 50-227, Poland
  • Clinical Trial Site
    Wroclaw, 54-617, Poland
  • Clinical Trial Site#1
    Belgrade, 11000, Serbia
  • Clinical Trial Site#2
    Belgrade, 11000, Serbia
  • Clinical Trial Site#1
    Kovin, 26220, Serbia
  • Clinical Trial Site#2
    Kovin, 26220, Serbia
  • Clinical Trial Site#1
    Kragujevac, 34000, Serbia
  • Clinical Trial Site#2
    Kragujevac, 34000, Serbia
  • Clinical Trial Site#3
    Kragujevac, 34000, Serbia
  • Clinical Trial Site
    Nis, 11000, Serbia
  • Clinical Trial Site
    Barcelona, 08036, Spain
  • Clinical Trial Site
    Oviedo, 33011, Spain
  • Clinical Trial Site
    Salamanca, 37005, Spain
  • Clinical Trial Site
    Valladolid, 47016, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Mar 2022, 18 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 9, 2020
StartActual
Aug 18, 2020
Primary completionActual
Mar 16, 2022
CompletionActual
Mar 16, 2022
Results first posted
Jun 15, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04421456
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Aug 18, 2020
Primary completion
Mar 16, 2022
Completion
Mar 16, 2022
Results posted
Jun 15, 2023
Last update
Jun 15, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion